Scancell DNA Immunotherapy Technology Granted Patent In Australia

Tue, 03rd Sep 2013 10:44

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that it had been granted a patent for its DNA ImmunoBody technology in Australia.

Scancell is an immunotherapy developer that produces vaccines for the treatment of cancer.

"Our lead ImmunoBody for melanoma, SCIB1, currently in Phase I/II clinical trials is based on the DNA approach," said Joint Chief Executive Dr.Richard Goodfellow in a statement. "The approval of this DNA patent is therefore a very important step in the development of our ImmunoBody platform. "

Scancell's shares were trading up 3.9% at 34.82 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Related Shares

More News

26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic....

5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

17 Jan 2024 14:26

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval fro...

19 Dec 2023 13:35

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of share...